CONFLICTLIVE
Global Disease Outbreak

US Flu Season Ends With 149 Child Deaths Amid Vaccine Policy Upheaval

The 2025–26 US flu season is closing with nearly 150 pediatric deaths and a vaccine effectiveness study, while federal policy shifts raise concerns.

Pediatric nurse administering flu vaccine to a child at a clinic

Overview

The 2025–26 influenza season in the United States is drawing to a close, but the numbers it leaves behind are sobering. As of late April 2026, the Centers for Disease Control and Prevention (CDC) has confirmed at least 149 pediatric influenza deaths for the current season — a toll that builds on a broader picture of roughly 31 million illnesses, 380,000 hospitalizations, and 23,000 total deaths nationwide. The season is winding down as measured by syndromic surveillance, yet weekly CDC reports continue to add to the pediatric count, underscoring that the virus remains active in some communities even as the peak recedes.

What makes this toll particularly significant from a public health standpoint is what it reveals about a persistent and addressable gap: the majority of children who died were unvaccinated. A newly published study covering the 2023–24 season found that influenza vaccination reduced flu-related hospitalization and outpatient visits in children by roughly 60%. The arithmetic is uncomfortable. An effective preventive tool exists, is widely available, and is underused — and children are paying the price.

Beyond the epidemiology, the season is closing against a backdrop of turbulence in U.S. federal public health leadership that has direct implications for vaccine confidence and international disease prevention. Reports of withheld international vaccine funding, shifts in the surgeon general nomination, and government-issued public health messaging that researchers say could erode vaccine trust have combined to make the spring of 2026 an unusually fraught moment for U.S. infectious disease policy.

Current Situation

The CDC’s weekly influenza surveillance updates through late April have continued to log pediatric deaths even as overall activity ebbs. The agency reported six additional child deaths in one update and four more in a prior week, with the cumulative 2025–26 total standing at 149 as of late April 2026, according to CIDRAP reporting on CDC data. Most of those deaths occurred in children who had not received the influenza vaccine.

The broader season-to-date burden is substantial: the CDC estimates approximately 31 million influenza illnesses, 380,000 hospitalizations, and 23,000 deaths across all age groups for the current season. These figures are in line with moderate-to-severe seasons in recent years, though the pediatric death total tracks toward the higher end of recent history.

A case report published in late April adds clinical texture to the aggregate statistics. Researchers documented a rare but severe complication in an adolescent: flu-related encephalopathy that triggered an adrenal crisis, requiring approximately three months of hospitalization. The patient ultimately recovered, though residual neurological deficits persisted at discharge. The case is notable not because it is common — flu-related encephalopathy affecting the adrenal axis in adolescents is rare — but because it illustrates the range of serious outcomes that influenza can produce, particularly in young patients whose complications may initially present as something other than a straightforward respiratory illness.

Separately, CDC surveillance flagged elevated rotavirus activity across the United States in mid-April, a reminder that as influenza wanes, other vaccine-preventable respiratory and gastrointestinal pathogens can move into the epidemiological foreground.

Affected Regions

Influenza activity during the 2025–26 season followed a pattern broadly consistent with prior years: spreading from the South and Southeast during autumn and winter, peaking nationally in January and February, and gradually retreating by late March and April. By mid-to-late April, the CDC characterized activity as ebbing, with widespread or high activity no longer reported in most states.

The pediatric deaths, while distributed nationally, have not been confined to any single geographic cluster. The syndrome is diffuse by nature — influenza circulates wherever unvaccinated or under-vaccinated children are, and the U.S. vaccination coverage map has persistent low spots in rural communities, some urban pockets, and regions where vaccine hesitancy is elevated.

Internationally, this season’s influenza trajectory in the United States fits within a broader Northern Hemisphere pattern. The World Health Organization has not declared the current H1N1 or H3N2 strains to represent a novel threat, and pandemic risk assessment remains low. However, ongoing co-circulation of multiple influenza A and B lineages continues to complicate strain-match predictions for future vaccine formulations.

Risk Assessment

The central risk finding of this season is not novel, but the new data sharpens it considerably. Research covering the 2023–24 season — the most recent for which complete effectiveness data are available — found that flu vaccination in children was associated with a 60% reduction in both flu-related hospitalizations and outpatient medical visits. That effectiveness figure is stronger than what has been measured in some prior seasons and reinforces the clinical case for annual pediatric vaccination.

The most vulnerable populations, as in prior seasons, are children under 5 years old (particularly infants under 6 months, who are too young for vaccination and rely on maternal and household immunity), children with underlying medical conditions, and — critically — previously healthy children who were simply unvaccinated. The last category is policy-actionable, which is part of what makes the persistent coverage gap so concerning.

The majority of this season’s 149 pediatric influenza deaths occurred in unvaccinated children — a pattern repeated year after year that underscores vaccination as the single most effective lever for reducing child flu mortality.

The rare but documented risk of severe neurological complications, as illustrated by the adrenal crisis case, extends the risk calculus beyond the typical hospitalization metric. Flu-related encephalopathy, while uncommon, can produce lasting deficits even in patients who survive, and it is disproportionately reported in pediatric and young adult populations.

A complicating factor in the 2025–26 risk environment is the state of public trust in vaccines and vaccine institutions. A new survey published in late April found that 69% of Americans trust vaccine scientists at least a “moderate amount” — a number that, while majority positive, still leaves a substantial minority with low or no trust. A separate global health misinformation survey found that roughly seven in ten people surveyed held at least one belief about health that contradicts established medical science, suggesting the trust deficit is not a uniquely American phenomenon.

The concern is not merely academic. Research published concurrently found that anti-science messaging — including messaging that has appeared in CDC-issued communications under current HHS leadership — can measurably erode public confidence in vaccines. If official public health messaging from the federal government begins to reinforce rather than counter vaccine hesitancy, the downstream effect on coverage rates and mortality could be significant.

Prevention & Response

The primary prevention tool for influenza is annual vaccination, and its effectiveness in the pediatric population is well-documented. For the 2025–26 season, the CDC continued to recommend vaccination for everyone aged 6 months and older, with particular emphasis on young children, pregnant women, adults 65 and older, and individuals with chronic health conditions.

The challenge is not the vaccine; it is getting it into arms. Coverage among school-age children has remained persistently below levels needed to meaningfully reduce community transmission. Public health officials and pediatricians have repeatedly identified several barriers: appointment access, cost and insurance gaps in some populations, parental hesitancy, and — increasingly — conflicting signals from public figures and, reportedly, from official government channels.

On the policy front, the U.S. surgeon general nomination has shifted. Dr. Janette Nesheiwat, the original nominee, was withdrawn, and Dr. Nicole Saphier — a physician and Fox News medical contributor — has been nominated as a replacement. Dr. Saphier has espoused some views on vaccines that researchers and public health advocates consider outside the mainstream scientific consensus, though she has also expressed support for childhood immunization in other contexts. The nomination, if confirmed, will place her in a role with significant influence over the government’s health communication posture.

Internationally, reports indicate that HHS Secretary Robert F. Kennedy Jr. has delayed the distribution of approximately $600 million in vaccine funding to foreign nations. Gavi, the Vaccine Alliance, which coordinates vaccine delivery in low- and middle-income countries, stated it has received no funding from the United States for the current year or the prior year. Kennedy has cited concerns about thimerosal — a mercury-containing preservative used in some multi-dose vaccine formulations in low-resource settings — as a factor in the hold. Scientists note that thimerosal contains ethylmercury, which the body processes and excretes quickly, rather than methylmercury, the form associated with neurological toxicity. If the funding freeze persists, the effect could be felt not only in those countries’ childhood immunization programs, but also in global surveillance capacity for emerging pathogens — a feedback loop with direct implications for pandemic preparedness.

For parents and caregivers, the immediate public health message is straightforward: annual influenza vaccination remains safe, widely available, and significantly effective at preventing serious illness and death in children. Consult a pediatrician about timing, particularly for children under 9 receiving the flu vaccine for the first time, who may require two doses. Children under 6 months should be protected through vaccination of household contacts and caregivers.

Sources

Sources